Article info

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

Authors

  1. Correspondence to Professor Masataka Kuwana, Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan; kuwanam{at}nms.ac.jp
View Full Text

Citation

Kuwana M, Blair C, Takahashi T, et al
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

Publication history

  • Received September 5, 2019
  • Revised February 25, 2020
  • Accepted February 25, 2020
  • First published March 11, 2020.
Online issue publication 
April 15, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.